Listen to Codrin Arsene interview Michael Klein, the CEO @ iCAD, one of the few FDA-approved artificial intelligence solutions for radiologists.
iCAD’s AI analyzes hundreds of data-points to deliver powerful software solutions for breast tomosynthesis, breast density and 2D mammography.
In simple terms, the iCAD software (Profound AI) analyzes mammogram images to produce cancer probability scores for radiologists.
Whereas iCAD cannot officially ‘diagnose’ breast cancer, the software alerts radiologists of any abnormalities tied to mammogram images for further inspection.
In the clinical trial which led to iCAD getting FDA approval, Profound AI was responsible for detecting 8% more cancers than the group of radiologists that analyzed the same data set.
Listen to the podcast to learn about:
– the history of iCAD
– Profound AI solution
– New exciting features and functionalities iCAD plans to release later this year
– The future of AI in healthcare.
iCAD was also previously included in the 2019 Healthcare Weekly Annual Artificial Report which can be read here.
Subscribe to ‘Healthcare Weekly: At the Forefront of Healthcare Innovation’ podcast on your favorite podcast network, today! New episodes released every week.
You may also want to check out a few additional recent episodes of the ‘Healthcare Weekly: At the Forefront of Healthcare Innovation‘ podcast: